|
Oct. 01, 2018 |
|
|
Sept. 10, 2019 |
|
|
jRCT2080224071 |
K-755 Phase 1 study |
|
K-755 Phase 1 study |
Kowa Company, Ltd. |
||
ctrdinfo@kowa.co.jp |
Kowa Company, Ltd. |
||
ctrdinfo@kowa.co.jp |
completed |
Sept. 24, 2018 |
||
| 78 | ||
Interventional |
||
DBT |
||
other |
||
1 |
||
healthy males |
||
subjects who having a history of drug allergy |
||
| 20age old over | ||
| 35age old under | ||
Male |
||
healthy males |
||
investigational material(s) |
||
safety |
||
safety |
||
| Kowa Co., Ltd. | |
| - |
| - | |
| - |
| Medical Corporation Heishinkai OPHAC Hospital | |
| 4-1-29 Miyahara, Yodogawa-ku, Osaka-shi, Osaka | |
+81-6-6395-9000 |
|
| sumiko.kawamoto@heishinkai.com | |
| approved | |
Sept. 21, 2018 |
| JapicCTI-184132 | |
| Japan |